Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers by Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H, Dubois T

Get full text

First results of tests on the WEAVE fibres by Sayède, F, Younes, Y, Fasola, G, Dorent, S, Abrams, D, Aguerri, J, Bonifacio, P, Dalton, G, Dee, K, Laporte, P, Lewis, I, Lhome, E, Middleton, K, Pragt, J, Rey, J, Stuik, R, Trager, S, Vallenari, A